Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16541610 | 1.00 | DRD2 (0.40) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL2219507 | 1.00 | DRD2 (0.40) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL12514180 | 0.82 | DRD2 (0.43) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL2219608 | 0.80 | DRD2 (0.43) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL12514607 | 0.80 | DRD2 (0.43) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL2219619 | 0.80 | DRD2 (0.43) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL30199537 | 0.79 | DRD2 (0.41) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL224930 | 0.77 | EPHX1 (0.51) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL11921121 | 0.77 | EPHX1 (0.51) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL224929 | 0.77 | EPHX1 (0.51) | DRD2EPHX1BTKDRD3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969405-B2 | Anticancer compounds and methods of making and using same | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2015-03-03 | — | — | US | disclosed |
| US-20110178098-A1 | ANTICANCER COMPOUNDS AND METHODS OF MAKING AND USING SAME | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178098-A1 | ANTICANCER COMPOUNDS AND METHODS OF MAKING AND USING SAME | MKI67, MCL1, BAD | DRD2 3942/4885EPHX1 3563/4885BTK 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.